4/16
09:23 am
lexx
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]
High
Report
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]
4/16
09:10 am
lexx
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Medium
Report
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
4/2
09:29 am
lexx
Lexaria Awarded New Patents [Yahoo! Finance]
Low
Report
Lexaria Awarded New Patents [Yahoo! Finance]
4/2
09:00 am
lexx
Lexaria Awarded New Patents
Low
Report
Lexaria Awarded New Patents
3/21
09:29 am
lexx
Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]
High
Report
Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]
3/14
09:26 am
lexx
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer [Yahoo! Finance]
3/14
09:20 am
lexx
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
High
Report
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
3/7
09:16 am
lexx
Lexaria Awards Contract For Next GLP-1 Human Pilot Study [Yahoo! Finance]
Low
Report
Lexaria Awards Contract For Next GLP-1 Human Pilot Study [Yahoo! Finance]
3/7
09:05 am
lexx
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Medium
Report
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
3/5
12:59 pm
lexx
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes [Seeking Alpha]
Medium
Report
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes [Seeking Alpha]
3/5
11:43 am
lexx
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target raised by analysts at Maxim Group from $3.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target raised by analysts at Maxim Group from $3.00 to $12.00. They now have a "buy" rating on the stock.
3/5
09:17 am
lexx
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 [Yahoo! Finance]
Medium
Report
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 [Yahoo! Finance]
3/5
09:05 am
lexx
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Medium
Report
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
3/4
09:37 am
lexx
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study [Yahoo! Finance]
Medium
Report
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study [Yahoo! Finance]
3/4
09:15 am
lexx
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Medium
Report
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
3/1
08:32 am
lexx
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial [Yahoo! Finance]
High
Report
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial [Yahoo! Finance]
3/1
08:20 am
lexx
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
High
Report
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
2/18
09:04 am
lexx
This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year [Yahoo! Finance]
Medium
Report
This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year [Yahoo! Finance]
2/16
04:05 pm
lexx
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
High
Report
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2/15
08:05 am
lexx
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
High
Report
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
2/15
08:00 am
lexx
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Medium
Report
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
1/30
11:00 am
lexx
Lexaria submits IND to begin Phase 1b study of DehyraTECH-CBD [Seeking Alpha]
Low
Report
Lexaria submits IND to begin Phase 1b study of DehyraTECH-CBD [Seeking Alpha]
1/30
09:03 am
lexx
Lexaria's Submits Investigational New Drug Application [Yahoo! Finance]
Medium
Report
Lexaria's Submits Investigational New Drug Application [Yahoo! Finance]
1/30
08:45 am
lexx
Lexaria's Submits Investigational New Drug Application
Medium
Report
Lexaria's Submits Investigational New Drug Application